Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that clinical data on nedosiran, an investigational candidate for the treatment of primary hyperoxaluria (PH), will be presented during the American Society of Nephrology (ASN) Kidney Week taking place Oct. 22-25, 2020. In addition, a commercial claims analysis of clinical and economic burden associated with PH will also be presented.
The following poster presentations will be available during the “Genetic Diseases of the Kidneys: Non-Cystic – 1” session taking place on Thursday, Oct. 22, 2020 at 10:00 a.m. ET:
Title: PHYOX™3: A Long-Term, Open-Label Extension Trial of Nedosiran in Patients With Primary Hyperoxaluria Type 1, 2 or 3
Poster #: PO1625
About Primary Hyperoxaluria
Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. There are three known types of